| Literature DB >> 34177873 |
Ting Shi1, Xiang-Qian Li1,2, Li Zheng3,4, Ya-Hui Zhang5,6, Jia-Jia Dai1, Er-Lei Shang7, Yan-Yan Yu1, Yi-Ting Zhang1, Wen-Peng Hu1, Da-Yong Shi1,2.
Abstract
The fungal strains Pseudogymnoascus are a kind of psychrophilic pathogenic fungi that are ubiquitously distributed in Antarctica, while the studies of their secondary metabolites are infrequent. Systematic research of the metabolites of the fungus Pseudogymnoascus sp. HSX2#-11 led to the isolation of six new tremulane sesquiterpenoids pseudotremulanes A-F (1-6), combined with one known analog 11,12-epoxy-12β-hydroxy-1-tremulen-5-one (7), and five known steroids (8-12). The absolute configurations of the new compounds (1-6) were elucidated by their ECD spectra and ECD calculations. Compounds 1-7 were proved to be isomeride structures with the same chemical formula. Compounds 1/2, 3/4, 1/4, and 2/3 were identified as four pairs of epimerides at the locations of C-3, C-3, C-9, and C-9, respectively. Compounds 8 and 9 exhibited cytotoxic activities against human breast cancer (MDA-MB-231), colorectal cancer (HCT116), and hepatoma (HepG2) cell lines. Compounds 9 and 10 also showed antibacterial activities against marine fouling bacteria Aeromonas salmonicida. This is the first time to find terpenoids and steroids in the fungal genus Pseudogymnoascus.Entities:
Keywords: Antarctic fungus; Pseudogymnoascus sp. HSX2#-11; antibacterial activity; cytotoxicity; sesquiterpenoids; steroids
Year: 2021 PMID: 34177873 PMCID: PMC8226235 DOI: 10.3389/fmicb.2021.688202
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Structures of compounds 1–12.
Cytotoxicities (IC50, μM) of compounds 8 and 9.
| MDA-MB-231 | 30 ± 2.0 | 27 ± 1.7 |
| A549 | >40 | >40 |
| HCT116 | 25 ± 1.5 | 23 ± 0.93 |
| HepG2 | 21 ± 1.0 | 23 ± 1.3 |
| PANC-1 | >40 | >40 |
FIGURE 2Phylogenetic tree of the fungus Pseudogymnoascus sp. HSX2#-11.
1H NMR data of compounds 1–6 in CDCl3 at 600 MHz.
| 1 | 2.71, t (10.5) | |||||
| 3 | 3.03–2.99, m | 3.14–3.08, m | 3.15, d (12.1) | 3.03, d (12.2) | 3.16, dt (12.1, 2.8) | |
| 4 | 2.23, dd (13.5, 6.1) | 1.95, ddt (14.0, 5.3, 2.7) | 1.96, ddt (13.3, 5.5, 2.8) | 2.25, dd (14.1, 6.2) | 2.47, d (16.9) | 2.01–1.96, m |
| 1.75, dd (13.5, 6.2) | 1.62, ddd (14.0, 12.5, 2.1) | 1.63, ddd (13.3, 12.1, 2.1) | 1.88–1.78, m | 2.38–2.29, m | 1.65, d (13.2) | |
| 5 | 2.05, dd (14.2, 8.5) | 2.03–1.98, m | 2.04–1.99, m | 2.11–2.04, m | 1.71–1.62, m | 2.05–2.02, m |
| 1.47, td (14.2, 6.2) | 1.77, dt (13.5, 2.7) | 1.81–1.79, m | 1.49, dt (13.3, 6.2) | 1.79, t (13.2) | ||
| 6 | 2.11–2.07, m | 1.91–1.86, m | 1.91, dq (7.0, 3.0) | 2.17–2.11, m | 2.08–2.00, m | 1.96–1.91, m |
| 7 | 3.10–3.03, m | 2.89–2.83, m | 2.98–2.92, m | 3.16, br s | 2.08–2.00, m | 2.91–2.86, m |
| 8 | 1.82–1.77, m | 1.82–1.79, m | 1.58, t (12.0) | 1.60, t (12.0) | 1.60–1.56, m | 1.69, d (12.0) |
| 1.41, t (12.5) | 1.40, dd (13.3, 10.7) | 1.50, dd (12.0, 8.4) | 1.42, dd (12.0, 7.3) | 1.53–1.50, m | 1.46, dd (12.0, 8.1) | |
| 10 | 2.32, d (17.5) | 2.13, d (16.1) | 2.07, d (15.7) | 2.17–2.11, m | 3.64, dd (10.5, 6.2) | 3.73, s |
| 1.90, d (17.5) | 1.86–1.82, m | 1.85–1.81, m | 2.11–2.04, m | |||
| 11 | 4.67, d (10.3) | 4.75, d (13.2) | 4.75, d (13.3) | 4.67, d (12.0) | 4.91, d (17.8) | 5.00, d (13.6) |
| 4.65, d (10.3) | 4.69, d (13.2) | 4.68, d (13.3) | 4.62, d (12.0) | 4.81, d (17.8) | 4.88, d (13.6) | |
| 13 | 0.93, d (7.2) | 0.88, d (6.9) | 0.86, d (7.0) | 0.93, d (7.1) | 0.96, d (5.8) | 0.91, d (7.0) |
| 14 | 1.11, s | 1.12, s | 0.92, s | 1.06, s | 0.95, s | 1.07, s |
| 15 | 3.46, d (10.6) | 3.30, d (10.6) | 3.52, s | 3.49, s | 1.07, s | 0.82, s |
| 3.39, d (10.6) | 3.26, d (10.6) |
13C NMR data of compounds 1–6 in CDCl3 at 150 MHz.
| 1 | 138.5, C | 138.8, C | 138.4, C | 138.0, C | 45.0, CH | 140.8, C |
| 2 | 125.0, C | 125.6, C | 125.8, C | 125.2, C | 162.9, C | 132.6, C |
| 3 | 43.56, CH | 44.5, CH | 44.6, CH | 43.6, CH | 128.8, C | 44.7, CH |
| 4 | 26.5, CH2 | 22.7, CH2 | 22.6, CH2 | 26.5, CH2 | 20.1, CH2 | 22.2, CH2 |
| 5 | 33.1, CH2 | 36.9, CH2 | 36.9, CH2 | 33.2, CH2 | 33.5, CH2 | 36.9, CH2 |
| 6 | 32.7, CH | 31.5, CH | 31.5, CH | 32.6, CH | 32.7, CH | 30.7, CH |
| 7 | 43.59, CH | 48.4, CH | 47.7, CH | 43.2, CH | 41.5, CH | 47.5, CH |
| 8 | 40.8, CH2 | 40.1, CH2 | 39.7, CH2 | 40.6, CH2 | 42.3, CH2 | 41.1, CH2 |
| 9 | 42.6, C | 43.8, C | 43.9, C | 42.8, C | 39.0, C | 42.6, C |
| 10 | 41.2, CH2 | 41.5, CH2 | 41.6, CH2 | 41.1, CH2 | 83.6, CH | 80.1, CH |
| 11 | 69.20, CH2 | 69.6, CH2 | 69.6, CH2 | 69.2, CH2 | 71.1, CH2 | 68.9, CH2 |
| 12 | 177.8, C | 179.3, C | 179.3, C | 177.8, C | 175.3, C | 178.6, C |
| 13 | 17.5, CH3 | 12.0, CH3 | 12.1, CH3 | 17.7, CH3 | 12.1, CH3 | 12.9, CH3 |
| 14 | 24.3, CH3 | 23.6, CH3 | 22.7, CH3 | 23.2, CH3 | 23.9, CH3 | 22.1, CH3 |
| 15 | 69.18, CH2 | 68.9, CH2 | 71.2, CH2 | 71.5, CH2 | 29.1, CH3 | 25.7, CH3 |
FIGURE 3Key COSY and HMBC correlations of compounds 1–6.
FIGURE 4Key NOESY correlations of compounds 1–4 and 6.
FIGURE 5Experimental ECD spectra of compounds 1–6.
FIGURE 6Experimental and calculated ECD of compounds 1–6.
FIGURE 7Proposed biosynthetic pathway for 1–7.
FIGURE 8Inhibition rates of tested cell lines of compounds 8 and 9.
FIGURE 9Inhibition rates of A. salmonicida of compounds 9 and 10.